Editor's Note Glucagon-like peptide-1 receptor agonists (GLP-1s) could reduce total knee arthroplasty (TKA) complications for non-diabetic patients with obesity, according to a November 13 Helio report on research presented at the American Association of Hip and Knee Surgeons Annual Meeting. In addition to reduced odds of 90-day medical complications, the…
Editor's Note The US Food and Drug Administration (FDA) has updated the labels of all treatments containing GLP-1 receptor agonists with a warning about warning about pulmonary aspiration during general anesthesia or deep sedation. Drugs and brand names listed in a November 8 report on the development from MedPage Today…
Editor's Note Joint guidance from key US medical associations advises that most patients on GLP-1 weight-loss medications, such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro), may safely continue these drugs before surgery, HealthDay News reported October 31. Concerns had emerged about potential risks associated with these medications due to their…
Editor's Note Combining newer weight loss drugs with bariatric surgery is the most cost-effective long-term strategy for treating obesity, according to research presented at the American College of Surgeons Clinical Congress 2024. Medical Xpress reported on the findings October 18. According to the article, researchers from Northwestern Medicine evaluated the…
Editor's Note Patients using GLP-1 receptor agonists (GLP-1 RAs) have a higher risk of food retention during esophagogastroduodenoscopy (EGD) when performed alone, but not when combined with a colonoscopy, according to a retrospective study from Cedars-Sinai Medical Center. MedPage Today reported the news October 1. The study included 70 patients…
Editor's Note Bariatric surgery significantly reduces the progression of chronic kidney disease (CKD) in patients with type 2 diabetes and obesity compared to those on GLP-1 diabetes medications, according to a study from Cleveland Clinic. Published in Annals of Surgery and detailed in a September 20 announcement from Cleveland Clinic,…
Editor's Note Patients prescribed a glucagon-like peptide-1 agonist (GLP-1) showed higher postoperative infection rates after ankle-fusion procedures in a study presented at the annual meeting of the American Orthopaedic Foot & Ankle Society. Healio reported the news September 20. Conducted by a team at the Milton S. Hershey Medical…
Editor's Note Research shows atrial fibrillation (Afib), a heart rhythm disorder, affects 10.5 million US adults—three times more than previously believed, HealthDay News reported September 12. The article focuses on a study from the University of California, San Francisco (UCSF), published in the Journal of the American College of Cardiology.…
Editor's Note Findings to be presented at the American Heart Association's Hypertension Scientific Sessions 2024 suggest bariatric surgery may offer more effective long-term control of high blood pressure for people with obesity compared to medications and lifestyle changes, according to a September 5 report in News Medical. According to the…
Editor's Note A shuttered bariatric surgery center in Oklahoma last month is just one example of how the rise of Glucagon-like peptide-1 (GLP-1) agonists are reshaping health systems’ investments, Axios reported August 13. Rather than “massive hospital towers with cardiology clinics, dialysis beds and joint replacement centers,” the focus is…